Figure 3.
Clinicopathological parameters and CBX mRNA levels in STAD patients (UALCAN): (a) correlation between the expression level of CBXs and nodal metastatic status in STAD patients (UALCAN, ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001); (b) correlation between expression of CBXs and individual cancer stage in STAD patients (UALCAN, ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001).